LEXARIA BIOSCIENCE CORP (LEXX)

US52886N4060 - Common Stock

1.93  -0.13 (-6.31%)

Premarket: 1.92 -0.01 (-0.52%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LEXX. LEXX was compared to 195 industry peers in the Pharmaceuticals industry. LEXX has a great financial health rating, but its profitability evaluates not so good. LEXX is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEXX has reported negative net income.
LEXX had a negative operating cash flow in the past year.
In the past 5 years LEXX always reported negative net income.
In the past 5 years LEXX always reported negative operating cash flow.

1.2 Ratios

LEXX's Return On Assets of -74.74% is on the low side compared to the rest of the industry. LEXX is outperformed by 72.58% of its industry peers.
LEXX has a Return On Equity (-74.89%) which is in line with its industry peers.
Industry RankSector Rank
ROA -74.74%
ROE -74.89%
ROIC N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 99.45%, LEXX belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
LEXX's Gross Margin has improved in the last couple of years.
LEXX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%

More info and screens

8

2. Health

2.1 Basic Checks

LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LEXX has more shares outstanding
LEXX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 1030.34 indicates that LEXX is not in any danger for bankruptcy at the moment.
LEXX has a better Altman-Z score (1030.34) than 100.00% of its industry peers.
LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1030.34
ROIC/WACCN/A
WACC9.23%

2.3 Liquidity

LEXX has a Current Ratio of 29.64. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX has a Current ratio of 29.64. This is amongst the best in the industry. LEXX outperforms 97.31% of its industry peers.
LEXX has a Quick Ratio of 29.64. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX's Quick ratio of 29.64 is amongst the best of the industry. LEXX outperforms 97.31% of its industry peers.
Industry RankSector Rank
Current Ratio 29.64
Quick Ratio 29.64

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.68% over the past year.
LEXX shows a strong growth in Revenue. In the last year, the Revenue has grown by 76.66%.
The Revenue has been growing by 16.11% on average over the past years. This is quite good.
EPS 1Y (TTM)43.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
Revenue 1Y (TTM)76.66%
Revenue growth 3Y-13.61%
Revenue growth 5Y16.11%
Sales Q2Q%18.98%

3.2 Future

Based on estimates for the next years, LEXX will show a very negative growth in Earnings Per Share. The EPS will decrease by -24.01% on average per year.
The Revenue is expected to grow by 221.49% on average over the next years. This is a very strong growth
EPS Next Y3.17%
EPS Next 2Y-2.09%
EPS Next 3Y-24.01%
EPS Next 5YN/A
Revenue Next Year39.2%
Revenue Next 2Y72.29%
Revenue Next 3Y107.51%
Revenue Next 5Y221.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

LEXX's earnings are expected to decrease with -24.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.09%
EPS Next 3Y-24.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (1/14/2025, 8:00:02 PM)

Premarket: 1.92 -0.01 (-0.52%)

1.93

-0.13 (-6.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-10 2025-01-10
Earnings (Next)N/A N/A
Inst Owners13.02%
Inst Owner Change0%
Ins Owners7.76%
Ins Owner Change40.88%
Market Cap33.68M
Analysts82.5
Price Target10.2 (428.5%)
Short Float %3.18%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.43%
Min EPS beat(2)-96.08%
Max EPS beat(2)-24.78%
EPS beat(4)1
Avg EPS beat(4)-25.76%
Min EPS beat(4)-96.08%
Max EPS beat(4)41.18%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.35%
Min Revenue beat(2)-52.94%
Max Revenue beat(2)-11.76%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-11.97%
EPS NY rev (3m)-11.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-30.41%
Revenue NY rev (3m)-30.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 67.77
P/FCF N/A
P/OCF N/A
P/B 3.45
P/tB 3.63
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.03
BVpS0.56
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.74%
ROE -74.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.45%
FCFM N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 231.33%
Cap/Sales 37.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.64
Quick Ratio 29.64
Altman-Z 1030.34
F-Score5
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)180.34%
Cap/Depr(5y)128.2%
Cap/Sales(3y)61.26%
Cap/Sales(5y)40.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
EPS Next Y3.17%
EPS Next 2Y-2.09%
EPS Next 3Y-24.01%
EPS Next 5YN/A
Revenue 1Y (TTM)76.66%
Revenue growth 3Y-13.61%
Revenue growth 5Y16.11%
Sales Q2Q%18.98%
Revenue Next Year39.2%
Revenue Next 2Y72.29%
Revenue Next 3Y107.51%
Revenue Next 5Y221.49%
EBIT growth 1Y-20.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.65%
OCF growth 3YN/A
OCF growth 5YN/A